Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous stromal vascular fraction + mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Black Tie Medical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous stromal vascular fraction (cSVF) combined with mesenchymal stem cells (MSCs) is a combination cell therapy protocol developed by Black Tie Medical for the treatment of Autism Spectrum Disorder (ASD). The therapy involves the isolation of cSVF from the patient's own adipose tissue, which contains a heterogeneous population of regenerative cells including stem cells, endothelial cells, and pericytes. This is supplemented with autologous MSCs that are isolated, concentrated, and cryopreserved for interval administration. The treatment aims to address the neuroinflammatory and immune dysregulation components of ASD through the immunomodulatory and anti-inflammatory properties of the transplanted cells. It is typically administered intravenously as part of a multimodal protocol that may also include dietary modifications and fecal microbiota transplantation.
- Other names
- autologous cSVF + MSCsautologous cellular stromal vascular fraction + mesenchymal stem cells
Beyond the preview
Go deeper on autologous stromal vascular fraction + mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous stromal vascular fraction + mesenchymal stem cells.